Učitavanje...
The RAF Inhibitor Paradox Revisited
The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF-mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transductio...
Spremljeno u:
Glavni autori: | , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
2012
|
Teme: | |
Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3285264/ https://ncbi.nlm.nih.gov/pubmed/22340588 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.01.017 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|